Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R, Herling AW, Bossart M, Weiss T, Zhang B, Wenski P, Wandschneider J, Kleutsch S, Butty U, Kannt A, Wagner M, Haack T, Evers A, Dudda A, Lorenz M, Keil S, Larsen PJ. Elvert R, et al. Among authors: wagner m. Diabetes Obes Metab. 2018 Aug;20(8):1836-1851. doi: 10.1111/dom.13212. Epub 2018 Jun 25. Diabetes Obes Metab. 2018. PMID: 29938884 Free PMC article.
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.
Evers A, Bossart M, Pfeiffer-Marek S, Elvert R, Schreuder H, Kurz M, Stengelin S, Lorenz M, Herling A, Konkar A, Lukasczyk U, Pfenninger A, Lorenz K, Haack T, Kadereit D, Wagner M. Evers A, et al. Among authors: wagner m. J Med Chem. 2018 Jul 12;61(13):5580-5593. doi: 10.1021/acs.jmedchem.8b00292. Epub 2018 Jun 25. J Med Chem. 2018. PMID: 29879354
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ. Tillner J, et al. Among authors: wagner m, wagner f. Diabetes Obes Metab. 2019 Jan;21(1):120-128. doi: 10.1111/dom.13494. Epub 2018 Sep 16. Diabetes Obes Metab. 2019. PMID: 30091218 Clinical Trial.
Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements.
Evers A, Pfeiffer-Marek S, Bossart M, Heubel C, Stock U, Tiwari G, Gebauer B, Elshorst B, Pfenninger A, Lukasczyk U, Hessler G, Kamm W, Wagner M. Evers A, et al. Among authors: wagner m. J Pharm Sci. 2019 Apr;108(4):1404-1414. doi: 10.1016/j.xphs.2018.11.043. Epub 2018 Dec 4. J Pharm Sci. 2019. PMID: 30528197
First-in-class positron emission tomography tracer for the glucagon receptor.
Velikyan I, Haack T, Bossart M, Evers A, Laitinen I, Larsen P, Plettenburg O, Johansson L, Pierrou S, Wagner M, Eriksson O. Velikyan I, et al. Among authors: wagner m. EJNMMI Res. 2019 Feb 15;9(1):17. doi: 10.1186/s13550-019-0482-0. EJNMMI Res. 2019. PMID: 30771019 Free PMC article.
6,503 results